Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer

Peter N. Morcos1 · Eveline Nueesch2 · Felix Jaminion3 · Elena Guerini3 · Joy C. Hsu1 · Walter Bordogna2 · Bogdana Balas2 · Francois Mercier3

Received: 13 April 2018 / Accepted: 1 May 2018 / Published online: 10 May 2018 © The Author(s) 2018

Abstract
Purpose Alectinib is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor that is active in the central nervous system (CNS). Alectinib demonstrated robust efficacy in a pooled analysis of two single-arm, open-label phase II studies (NP28673, NCT01801111; NP28761, NCT01871805) in crizotinib-resistant ALK-positive non-small-cell lung cancer (NSCLC): median overall survival (OS) 29.1 months (95% confidence interval [CI]: 21.3–39.0) for alectinib 600 mg twice daily (BID). We investigated exposure–response relationships from final pooled phase II OS and safety data to assess alectinib dose selection.

Methods A semi-parametric Cox proportional hazards model analyzed relationships between individual median observed steady-state trough concentrations ($C_{\text{trough,ss}}$) for combined exposure of alectinib and its major metabolite (M4), baseline covariates (demographics and disease characteristics) and OS. Univariate logistic regression analysis analyzed relationships between $C_{\text{trough,ss}}$ and incidence of adverse events (AEs: serious and Grade ≥ 3).

Results Overall, 92% of patients ($n = 207/225$) had $C_{\text{trough,ss}}$ data and were included in the analysis. No statistically significant relationship was found between $C_{\text{trough,ss}}$ and OS following alectinib treatment. The only baseline covariates that statistically influenced OS were baseline tumor size and prior crizotinib treatment duration. Larger baseline tumor size and shorter prior crizotinib treatment were both associated with shorter OS. Logistic regression confirmed no significant relationship between $C_{\text{trough,ss}}$ and AEs.

Conclusion Alectinib 600 mg BID provides systemic exposures at plateau of response for OS while maintaining a well-tolerated safety profile. This analysis confirms alectinib 600 mg BID as the recommended global dose for patients with crizotinib-resistant ALK-positive NSCLC.

Keywords Alectinib · ALK inhibitor · NSCLC · Exposure response · ER · Pharmacokinetics · Oncology

Introduction

Rearrangement of the anaplastic lymphoma kinase (ALK) gene occurs in approximately 5% of patients with advanced non-small-cell lung cancer (ALK-positive NSCLC) [1]. This disease is characterized by high risk of central nervous system (CNS) metastases [2], and a high prevalence of brain metastases at diagnosis [3, 4]. Crizotinib was the historic standard of care for first-line treatment of ALK-positive NSCLC, based on improved progression-free survival (PFS) compared with standard chemotherapy (10.9 months versus 7.7 months, respectively) in the phase III PROFILE 1014 trial [5]. However, many patients treated with crizotinib relapse within 1 year, primarily due to poor CNS penetration or development of resistance mutations [6, 7]. As such, there was an unmet medical need to overcome the challenges associated with crizotinib treatment.

Alectinib is a potent ALK tyrosine kinase inhibitor (TKI) with an IC$_{50}$ (50% of maximum inhibitory concentration) of 1.9 nmol/L in enzymatic analyses [8]. Alectinib has
demonstrated antitumor activity in preclinical models that are resistant to the previous standard of care, crizotinib, as well as CNS tumor models [9, 10]. Two single-arm, phase II studies (NP28673, global [NCT01801111] [11] and NP28761, North American [NCT01871805] [12]) demonstrated robust efficacy and an acceptable safety profile for alectinib 600 mg twice daily (BID) in patients with ALK-positive NSCLC following crizotinib failure. An updated pooled analysis for these studies at a median follow-up of 92.29 weeks demonstrated a median overall survival (OS) of 29.1 months (95% confidence interval [CI]: 21.3–39.0), and good tolerability over a median treatment duration of 11.3 months with alectinib [13]. The pivotal global, randomized, phase III ALEX study (BO28984, NCT02075840) confirmed the clinical benefit of first-line alectinib treatment for patients with ALK inhibitor naïve ALK-positive NSCLC [14]. In ALEX, the primary endpoint (investigator-assessed median PFS) was significantly improved with alectinib versus crizotinib: hazard ratio (HR) for disease progression or death was 0.47 (95% CI: 0.34–0.65; P < 0.001) [14]. Based on these cumulative data, the globally approved dosing regimen for alectinib is 600 mg BID.

Dose selection is a critical issue for development and registration of new molecular entities (NMEs). Optimal dose selection is achieved by maximizing the potential for efficacy, while minimizing the potential for safety risks in the target patient population, and is a key review issue by major health authorities during new drug application (NDA) reviews [15]. Identification of optimal dose selection is a challenging task during drug development, particularly in the field of oncology, where first-in-human studies primarily use conventional approaches originally tailored for cytotoxic chemotherapeutics and subsequent development programs focus on speed to approval [16–18]. The challenges associated with optimizing dose selection for oncology NMEs is highlighted in recent reviews of regulatory evaluations of NDAs [16, 19]. Indeed, in one review it is cited that more than one quarter of approved new oncology agents within an investigated period required further dose optimization investigations, with a greater trend reported for approved TKIs [19]. Thus, there is regulatory expectation to maximize the benefit/risk of the NME for approval and use in the intended patient population by justifying or investigating optimal dose selection.

To robustly justify dose selection for an NME, the cumulative available nonclinical and clinical data are generally considered to ensure its optimal use. A clinical evaluation of dose selection is based on the established efficacy and safety along with a thorough characterization of exposure–response relationships for those established efficacy and safety data. The following analyses examine the exposure–response relationships for alectinib in the crizotinib-resistant ALK-positive NSCLC population based on final pooled efficacy and safety data from the pivotal phase II North American study (NP28761; NCT01871805) and the phase II global study (NP28673; NCT01801111) to assess alectinib dose selection in this setting.

Materials and methods

Study design and patient population

The study designs for the two studies have been published previously [11, 12]. In brief, both were single-arm, open-label, multicenter studies that enrolled patients with ALK-rearranged, locally advanced or metastatic NSCLC, who experienced progression on, or were intolerant to, crizotinib therapy, with a primary objective to assess efficacy and safety. Inclusion criteria for both studies were: histologically confirmed, advanced ALK-rearranged NSCLC (as assessed by an FDA-approved test), progression on crizotinib treatment, aged ≥ 18 years with Eastern Cooperative Oncology Group performance status ≤ 2, adequate organ function, and measurable disease. Patients with stable treated brain and/or leptomeningeal metastases or asymptomatic untreated brain and/or leptomeningeal metastases were eligible for enrolment. A minimum 7-day wash-out period was required between the last crizotinib dose and the first alectinib dose [11, 12]. In both studies, patients received 600 mg oral alectinib administered with food BID until progression, death, or withdrawal. Both studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and all patients provided written informed consent.

Analysis data

The efficacy analysis dataset consisted of the final pooled OS data from the two individual single-arm phase II trials [13]. The pooled analysis assessed OS and safety after median follow-up of 92.29 weeks (NP28673: 105.5 weeks, data cut-off 27 October 2017; NP28761: 75.71 weeks, data cut-off 12 October 2017). The safety analysis dataset focused on 2 key safety events generally associated with overall tolerability of study drug: any serious adverse event (SAE) and any Grade ≥ 3 AE reported by patients during the study and throughout the follow-up period. Adverse events (AEs) were coded using Medical Dictionary for Regulatory Activities version 17.1; severity of AEs was coded according to the Common Terminology Criteria for Adverse Events version 4.0.

In both studies, approximately 2 mL of venous blood was collected in all patients for pharmacokinetic (PK) analysis of alectinib and its major active metabolite, M4, at various timepoints throughout the study periods [11, 12]. Alectinib...
and M4 plasma concentrations were determined simultaneously using validated liquid chromatography tandem mass spectroscopy using a separate laboratory for each study. Cross-validation experiments revealed an analytical bias of approximately 20% between the two laboratories and, therefore, concentrations of alectinib and M4 were adjusted to account for the analytical bias. Full details on the bioanalytical methodology for alectinib and M4 including cross-validation experiment results are presented elsewhere [20]. For both alectinib and M4, the observed steady-state trough concentration, defined as the median value of all available pre-dose concentrations in each patient collected after Day 8 (steady-state) of dosing was used as the exposure measure for exposure–response analyses. Patient samples were excluded if they were taken after drug administration or collected within 8 days of a documented dose deviation during the study. Both alectinib and its major metabolite, M4, have demonstrated similar in vitro potency and activity against the target ALK kinase and similar protein binding supporting that both analytes contribute to overall alectinib efficacy and safety [21]. Therefore, the combined exposure of alectinib and M4 (alectinib + M4) steady-state trough concentration adjusted for the individual molecular weights was utilized as the overall alectinib exposure measure (herein C_{trough,ss}) in the exposure–response analyses. This approach has been utilized for all other alectinib exposure investigations [22–25] and similarly utilized for exposure–response assessments for other agents with active metabolites [26–28].

**Exposure-efficacy analysis**

The primary efficacy measure explored in the exposure-efficacy analysis was OS reported from the final datacut of the pooled phase II analyses in the crizotinib-resistant patient population [13]. The relationship between alectinib exposure and OS was investigated using a semi-parametric Cox proportional hazards (CPH) model. The statistical methodology underpinning the analysis technique has been described in detail in a seminal paper [29]. Briefly, the survival analysis technique describes the relationship between the distribution of survival and pre-specified covariates [30]. A multiplicative model of the hazard could be described as:

\[ h_i(t) = h_0(t) \exp(\beta_1 x_{i1} + \beta_2 x_{i2} + \cdots + \beta_k x_{ik}). \]

Here, \( h_i(t) \) is the baseline hazard function, \( X_i = \{x_{i1}, x_{i2}, \ldots, x_{ik}\} \) is the vector of covariates for individual \( i \), and \( \beta_k \) is the coefficient which corresponds to covariate \( k \). The model assumes a baseline hazard which is common to all individuals included in the study population. The covariates have multiplicative effect on the baseline hazard. Further details can be found elsewhere [29, 30].

The investigation of the relationship between alectinib exposure along with baseline covariates and OS was conducted in two steps. First, a base model investigated the effect of alectinib exposure on OS without consideration of any potential effects of covariates. Several functional forms of alectinib exposure were considered to thoroughly investigate the potential exposure relationship to OS: linear continuous variables of exposure (\( C_{trough,ss} \) and the logarithm of \( C_{trough,ss} \)), linear categorical forms (halves and tertiles), and nonlinear forms (\( E_{max} \)-type function) were all investigated in the base model. The objective function value (\( OF \), corresponding to \( -2 \times \text{log-partial likelihood} \)) and the Bayesian Information Criterion (BIC) were used to select the best base model. BIC was computed as \( OF + p \times \log(n) \), where \( n \) is the number of observations and \( p \) is the number of model parameters. The model with the lowest BIC value was selected as the base model.

In the second step, covariates were investigated on the base model. Initially, a univariate screening was undertaken where every covariate was added one at a time to the base model. Covariates leading to a lower BIC values than the one observed with the base model were carried forward to the next model building step. The selected covariates were sequentially added (forward inclusion) to the base model and retained in a full covariate model if it further reduced the BIC value. After the full covariate model was developed, a backward elimination process was finally performed where covariates were excluded from the full model one at a time, and BIC values of the reduced and the full models were compared. The covariate was eliminated if the BIC value of the reduced model was lower than that of the full model. The final model, therefore, retained only the significant covariates influencing alectinib OS.

The adequacy of the final fitted CPH model was confirmed through creation of diagnostic plots. Schoenfeld residual plots were used to check the assumption of proportional hazards and examined whether there was any marked time-pattern in the residuals. Martingale residual plots were used to investigate any nonlinearity (i.e., an incorrectly specified functional form in the model) for each included covariate in the final model. Finally, a visual assessment of the performance of the final model was obtained by overlaying of the observed OS from the nonparametric Kaplan–Meier analysis of the pooled phase II studies to the final CPH model and associated 95% CIs.

**Exposure-safety analysis**

The relationship between alectinib exposure and the investigated safety endpoints, SAEs and Grade ≥ 3 AEs, was investigated through univariate logistic regression analyses. A Chi-square statistic was used for assessment of statistical significance of the relationship. In addition, the distribution of individual grades of AEs was assessed by graphically presenting the distribution of alectinib exposure by each grade of event for SAEs and Grade ≥ 3 AEs. An exploratory
analysis of variance (ANOVA) was used for assessment of statistical significance in the distributions by AE grades.

The analysis and all figures were conducted and produced using R (Version 3.2.4) [31].

Results

Population

A total of 225 patients were enrolled across both studies and received alectinib 600 mg BID [13]. The exposure–response population included 207 (92%) of these patients with available $C_{\text{trough,ss}}$ data. Baseline characteristics included in the analysis population are provided in Table 1. Overall the baseline factors from these patients were representative of the expected ALK-positive NSCLC population [31] and consistent with the overall population from the pooled phase II studies [13]. There were slightly more females than males and patients were generally young with a mean age of 52.3 years in the exposure–response population. The distribution of alectinib exposure ($C_{\text{trough,ss}}$) encompasses nearly a ninefold exposure range supporting a robust exploration of exposure–response relationships across wide exposures (Fig. 1).

Exposure-efficacy analysis

In the first step of the analysis, the base model which included the effect of exposure as the log($C_{\text{trough,ss}}$) was associated with the lowest BIC value of all explored exposure functional forms. A model evaluating an $E_{\text{max}}$-type exposure function resulted in a similar BIC; however, the estimated EC$_{50}$ parameter did not appear biologically reasonable and was associated with large imprecision (standard-error). Therefore, the model with log($C_{\text{trough,ss}}$) was taken forward as the base model. During the univariate screening of covariates, log(baseline tumor size), number of days of prior crizotinib treatment duration, body weight (BW), body mass index (BMI), and body surface area (BSA) were all associated with a decrease in BIC (Supplemental Table 1). Given BW, BMI, and BSA are correlated and BW showed the greatest change in BIC, only BW was subsequently investigated in an expanded model. During the forward addition process, the addition of log(baseline tumor size) and prior crizotinib treatment duration reduced the BIC relative to the reference models while BW did not improve the model (i.e., did not further reduce the BIC). Finally, during backward elimination of covariates, the removal of alectinib exposure reduced the BIC in this reduced model when compared with full model. The final model included the effects of log(baseline tumor size) and prior crizotinib treatment duration. No statistically significant effect of alectinib exposure was identified in the final CPH model (95% CI for an exposure effect includes 1).

Diagnostic plots of Schoenfeld residuals for the final model revealed no systematic deviations from horizontal for the smoothed fit of the scatter over time supporting the assumption of proportional hazards for both identified covariates (Fig. 2). Plots of Martingale residuals against the identified covariates in the final model illustrated no evidence for nonlinearity with the smoothed lines close to horizontal (Fig. 2). The performance of the final model is illustrated in an overlay plot showing that the final CPH model and associated 95% CIs capture well the observed OS in the corresponding nonparametric Kaplan–Meier analysis (Fig. 3).

Table 1 Summary of baseline covariates in the exposure–response population

| Covariate                                         | $n = 207$ |
|---------------------------------------------------|-----------|
| Race, $n$ (%)                                      |           |
| White                                             | 151 (72.9) |
| Asian                                             | 42 (20.3)  |
| Other                                             | 14 (6.8)   |
| Ethnicity, $n$ (%)                                 |           |
| Hispanic                                          | 17 (8.0)   |
| Non-hispanic                                      | 190 (92.0) |
| Sex, $n$ (%)                                       |           |
| Female                                            | 112 (54.0) |
| Male                                              | 95 (46.0)  |
| Age (years), mean (SD)                            | 52.3 (11.4) |
| Body weight (kg), mean (SD)                       | 73.5 (17.7) |
| Height (cm), mean (SD)                            | 168.1 (10.3) |
| BMI (Kg/m$^2$), mean (SD)                         | 25.9 (5.4)  |
| BSA (m$^2$), mean (SD)                            | 1.8 (0.2)   |
| Baseline tumor size (mm), mean (SD)               | 56.2 (45.0) |
| Smoking status at baseline, $n$ (%)                |           |
| Non-smoker                                        | 143 (69.1) |
| Past or present smoker                            | 64 (30.9)  |
| CNS metastases at baseline, $n$ (%)               |           |
| Yes                                               | 48 (23.0)  |
| No                                                | 159 (77.0) |
| Prior chemotherapy status, $n$ (%)                 |           |
| Yes                                               | 158 (76.0) |
| No                                                | 49 (24.0)  |
| Prior crizotinib treatment duration (days), mean (SD) | 438 (293.2) |
| Category of ECOG score at baseline, $n$ (%)       |           |
| ECOG score 0 or 1                                 | 185 (89.0) |
| ECOG score 2                                      | 22 (11.0)  |

$BMi$: Body mass index, $BSA$: body surface area, $ECOG$: Eastern Cooperative Oncology Group, $Geo$ mean: Geometric mean, $SD$: standard deviation, $CNS$: central nervous system
The covariates in the final model are illustrated in Fig. 4. Results provide an estimate HR (95% CI) for the 5th and 95th percentile of these continuous covariates relative to the median value. As seen in Fig. 4, larger baseline tumor size and shorter prior crizotinib treatment duration are associated with worse survival.

Exposure-safety analysis

Univariate logistic regression analyses for the relationship between alectinib exposure and incidence of SAEs or Grade ≥ 3 AEs revealed no apparent relationship across the nearly ninefold exposure range included in the analysis (Fig. 5). Statistical assessment supports no statistically significance for either SAEs or Grade ≥ 3 AE by Chi-square statistic (P = 0.465 and P = 0.978, respectively). The distribution of alectinib exposures by individual grades of SAEs or Grade ≥ 3 AEs further support no relationship between alectinib exposure and severity of safety events (P ≥ 0.597 by ANOVA) and illustrate substantial overlap in the distribution of exposure per safety event grade (Fig. 5). Of note, there was a low incidence (n = 3 [1.4%]) of Grade 5 safety events in the exposure–response population.

Discussion

Alectinib is a novel, CNS-active ALK inhibitor, which has demonstrated robust efficacy and good safety in patients with ALK-positive NSCLC who have progressed on, or are intolerant to, crizotinib treatment. Updated data from a pooled analysis of the phase II studies (NP28673; global [NCT01801111] and NP28761; North American [NCT01871805]) demonstrated a median OS of greater than 2 years in patients with pretreated ALK-positive NSCLC receiving alectinib, and a good tolerability profile [13].

Dose selection and justification are key elements in the development of new agents and central to the demonstration of benefit/risk. However, within the field of oncology, the approaches to dose selection appear antiquated and rely frequently on methodology developed for cytotoxic chemotherapies with a goal of identifying a maximally tolerated dose (MTD) [19]. This assumes that the maximal effect is linked to achieving the maximum dose/exposure approaching early toxicity in a small number of patients but often does not consider long-term safety as well as efficacy outcomes in justifying the selected dose. This has resulted in a large number of post-marketing requirements and commitments for dose optimization investigations for many newly registered agents [16, 19]. With the goal of dose selection to maximize the expected efficacy benefit while minimizing the expected toxicity, it is critical to investigate the relationship between exposure and long-term outcomes for justifying the selected dose.

The present analysis investigated the relationship between alectinib exposure and the key efficacy and safety outcomes from the final pooled phase II data in the crizotinib-resistant ALK-positive NSCLC population. The investigation of exposure–efficacy relationships was through a multivariate CPH analysis which considered the potential modulatory effects of 5 functional forms of exposure along with 14 covariates in contributing to the survival of patients. The use of CPH model for survival analysis is well established and enables an identification and quantification of covariates influencing outcomes [29, 30]. Additionally, the present analyses investigated the relationship between alectinib exposure and key safety endpoints.

The results of the exposure–response analyses of the pooled phase II studies demonstrated no significant effect of alectinib exposure on OS following administration of the recommended alectinib 600 mg BID dose in the crizotinib-resistant ALK-positive NSCLC population. This analysis indicates that patients derive similar benefit from alectinib treatment across the wide nearly ninefold exposure range when accounting for the modulatory effects of the identified significant covariates. These results justify the recommended global alectinib 600 mg BID dose selection to provide systemic exposures of alectinib within the plateau range of response for OS. Population PK analysis of alectinib previously showed that the major covariate influencing alectinib and M4 PK was BW, with higher BW associated with lower exposure [32]. The lack of exposure–response relationship seen here supports that no dose adjustments would be needed by BW. In addition, the results support that
no expected additional benefit in terms of improved efficacy is expected at dose/exposures exceeding the recommended alectinib 600 mg BID dose.

The analysis outcomes are complemented by a previously completed exploratory graphical pharmacokinetic/pharmacodynamic (PK/PD) analysis in the initial dose escalation, which showed that across the alectinib 300–900 mg BID dose range higher $C_{\text{trough,ss}}$ was associated with higher reduction in tumor size and a plateau appeared to be reached at $C_{\text{trough,ss}}$ corresponding to the 600 mg BID dose [32, 33]. That analysis suggested potential for reduced efficacy at doses/exposures lower than the 600 mg BID dose supporting it as the recommended alectinib global dose. Further, the primary analysis of the phase II studies showed that following alectinib 600 mg BID no significant relationship was seen between alectinib exposure and overall response rate (ORR) based on logistic regression analysis [11, 12, 32]. The present analysis builds on those initial observations by investigating the effect of exposure on long-term survival of patients. Of note, the previous exposure-ORR analysis utilized the population PK model predicted average concentration as the exposure measure. While that measure accounts for time on treatment and dose interruptions, the observed $C_{\text{trough,ss}}$ used in this analysis provides a clinically relevant and practical exposure measure for assessment of exposure–response relationships. In any case, the two exposure measures are high correlated ($r^2 > 0.8$) [Roche, data on file] supporting the use of either measure for analysis.
The results of this work contrast the outcomes seen from exposure–response analyses reported for the first generation ALK inhibitor, crizotinib [34–36]. While the recommended clinical dose for crizotinib was selected based on MTD, completed exposure–response analyses demonstrated a positive exposure–efficacy relationship suggesting that a proportion of patients receiving the approved crizotinib 250 mg BID dose may not be deriving full benefit from crizotinib therapy [34–36]. This resulted in an FDA mandated post-marketing commitment for further investigation of exposure–response relationships to evaluate the appropriateness of the approved 250 mg BID dose for all patients [34].

The final CPH analysis indicated that the major significant covariates impacting OS were the disease associated factors, baseline tumor size and prior crizotinib treatment duration. Baseline tumor size is frequently reported as a major covariate influencing the PK and/or PD of monoclonal antibodies as it contributes to target mediated drug disposition for antibodies targeting membrane bound antigens on tumor cells [37]. Given alectinib is a small molecule targeting the ALK kinase, the impact of baseline tumor size on OS from the alectinib phase II studies likely reflects the overall extent of disease burden in patients. Indeed, tumor size is an established prognostic factor for NSCLC with larger tumor size associated with poorer survival [38]. This was confirmed in an analysis of a large surveillance database containing more than 50,000 patients [39]. In this analysis, patients with a baseline tumor size representing the 95th percentile of the population were associated with a HR of 1.90 (95% CI: 1.38–2.61) relative to the median tumor size in the population. The other major covariate, prior crizotinib treatment duration, may be reflective of the overall health status of patients enrolled and/or their responsiveness to treatment. Patients within the 5th percentile of number of prior crizotinib treatment days were associated with a HR of 1.44 (95% CI: 1.15–1.80) relative to the median number of days. This may represent a poorer overall condition of some patients, which may not allow them to endure treatment. Alternatively, intratumoral heterogeneity could be contributing to treatment response for the targeted ALK inhibitors. In a prospective evaluation, an investigation of the evolution of NSCLC revealed widespread intratumor heterogeneity for both somatic copy-number alterations and mutations [40]. The intratumoral heterogeneity in NSCLC may contribute to resistance and/or progression after a period of treatment with targeted therapies, as only a portion of the heterogeneous tumor cells are destroyed on-treatment with the specific agent [41]. This could contribute to the shorter term responsiveness to crizotinib and subsequent shorter survival during alectinib treatment. Notwithstanding, the pooled analysis from the alectinib phase II studies demonstrated a clinically meaningful OS of greater than 2 years in patients already failing on crizotinib treatment, supporting its initial approval and use in this setting [13].

Interestingly, results from the analysis indicated that alectinib associated OS was not influenced by the presence of CNS metastases at baseline supporting benefit irrespective of this generally negative prognostic factor, albeit a relatively small sample size in the exposure–response population. These outcomes are supported by previously completed population PK analyses which demonstrated that alectinib PK is not influenced by presence of CNS metastases at
baseline [32]. Conversely, it has been reported that nearly half of patients treated with crizotinib progress in the CNS, likely negatively impacting survival [42, 43]. Unlike crizotinib, alectinib is not a substrate of drug efflux transporters, p-glycoprotein (P-gp) or breast cancer resistance protein (BCRP), which are located at the blood–brain barrier and, therefore, may effectively penetrate and be retained in the CNS [9]. More recently, alectinib decreased the risk of CNS progression by 84% compared with crizotinib in head-to-head investigation in the first-line phase III trial, ALEX [14].

Results from the exposure–response analyses of the pooled alectinib phase II studies also demonstrated no significant relationship between alectinib exposure and incidence or severity of safety events following administration of the alectinib 600 mg BID dose. While the distribution of Grade 5 events appears visually higher compared with lower grade events, this is driven by the very few (n = 3) events and ANOVA testing confirms lack of statistical significance. The lack of exposure relationship to safety events across the nearly ninefold exposure range confirms the tolerability of the alectinib 600 mg BID dose. These outcomes are consistent with the initial exposure–response investigations during the primary analyses of the phase II studies [32], and are supportive of the overall well-tolerated safety profile for alectinib. Indeed, in the pooled analyses, only 14.7% of patients experienced AEs leading to dose reductions and

---

**Fig. 5** Exposure-safety analysis. Top: univariate logistic regression analysis for the assessment of the relationship between $C_{\text{trough,ss}}$ and SAEs (left) or Grade ≥ 3 AEs (right). The black points represent the individual exposures for patients reporting (1.0) or not reporting (0.0) the safety event. The solid black line represents the logistic regression fit along with the 95% CIs (blue shading) for the fit; Bottom: Box-plot distributions of $C_{\text{trough,ss}}$ by grades of SAEs (left) or Grade ≥ 3 AEs (right). Median values of $C_{\text{trough,ss}}$ are designated by black lines in the center of the boxes. Boxes indicate the inter-quartile range (IQR). Whiskers represent 1.5*IQR. Outliers are marked outside of the whiskers by circles.
6.2% of patients experienced AEs leading to withdrawal over a median follow-up period of almost 2 years [13]. Conversely, completed exposure–response analyses for safety of another approved ALK inhibitor, ceritinib, showed a significant exposure-dependent effect on its toxicity [44, 45]. Given the poor tolerability and high incidence in dose reductions, an FDA mandated post-marketing requirement was issued for investigation of lower ceritinib doses to improve tolerability while maintaining its clinical benefit [44].

The present analysis has pooled two similarly designed phase II studies demonstrating similar results. Our analysis is, however, limited by the fact that the phase II studies were not designed to investigate exposure–response relationships and, therefore, this analysis is considered a post-hoc exploratory evaluation based on the data generated in the studies. In addition, while the completed CPH analysis investigated the potential effects of several functions of exposure and numerous covariates, there may still be unidentified risk factors influencing OS. Further, the CPH analysis may not entirely remove all confounding effects and does not account for potential interactions between covariates. Nonetheless, the favorable diagnostic plots and performance of the final CPH model evidenced in the visual assessment supports a robust final model in capturing OS. The lack of exposure-safety relationship across the wide exposure range supports the acceptable safety profile of alectinib.

**Conclusion**

Results from the exposure–response analyses demonstrate that the alectinib 600 mg BID dosing regimen provides systemic exposures of alectinib within the plateau of response for OS while achieving exposures not associated with increased risk of toxicity and thus maintaining the good tolerability of alectinib. These analyses justify the recommended alectinib 600 mg BID dose for the global crizotinib-resistant ALK-positive NSCLC population. This dosing regimen has been approved in more than 50 countries to-date.

**Acknowledgements** Third-party medical writing assistance, under the direction of the authors, was provided by Emma Evans, PhD of Gardiner-Caldwell Communications, and was funded by F. Hoffmann-La Roche Ltd.

**Funding** This analysis was funded by F. Hoffmann-La Roche Ltd (no grant number is applicable).

**Compliance with ethical standards**

**Conflict of interest** Peter N. Morcos is an employee of, and holds stocks/shares in, F. Hoffmann-La Roche Ltd. Eveline Nueesch is an employee of, and holds stocks/shares in, F. Hoffmann-La Roche Ltd. Felix Jamison is an employee of, and holds stocks/shares in, F. Hoffmann-La Roche Ltd. Elena Guerrini is an employee of, and holds stocks/shares in, F. Hoffmann-La Roche Ltd. Joy C. Hsu is an employee of, and holds stocks/shares in, F. Hoffmann-La Roche Ltd. Walter Bordogna is an employee of, and holds stocks/shares in, F. Hoffmann-La Roche Ltd. Bogdana Balas is an employee of, and holds stocks/shares in, F. Hoffmann-La Roche Ltd. Francois Mercier is an employee of F. Hoffmann-La Roche Ltd.

**Ethical approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed consent** Informed consent was obtained from all individual participants included in the studies.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Choi YL, Soda M, Yamashita Y et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734–1739
2. Rangachari D, Yamaguchi N, VanderLaan PA et al (2015) Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88:108–111
3. Johung KL, Yeh N, Desai NB et al (2015) Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34:123–129
4. Toyokawa G, Seto T, Takenoyama M et al (2015) Insights into brain metastasis in patients with ALK + lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev 34:797–805
5. Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177
6. Costa DB, Kobayashi S, Pandya SS et al (2011) CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29:e443–e445
7. Katayama R, Shaw AT, Khan TM et al (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 4:120ra17
8. Song Z, Wang M, Zhang A (2015) Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm Sin B 5:34–37
9. Kodama T, Hasegawa M, Takenashi K et al (2014) Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74:1023–1028
10. Kodama T, Tsukaguchi T, Yoshida M et al (2014) Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 351:215–221
11. Ou SH, Ahn JS, De Petris L et al (2016) Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34:661–668
12. Shaw AT, Gandhi L, Gadgeel S et al (2016) Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17:234–242
13. Ou SH, Leena Gandhi, Gadgeel S (2018) Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small Cell lung cancer (NSCLC). ASCO 2018 (abstract accepted as poster presentation)

14. Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829–838

15. Sacks LV, Shamsuddin HH, Yasinskaya YI, Bouri K, Lanthier N, Sherman RE (2014) Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000–2012. JAMA 311:378–384

16. Sachs JR, Mayawala K, Gadansetty S et al (2016) Optimal dosing for targeted therapies in oncology: drug development cases leading by example. Clin Cancer Res 22:1318–1324

17. Mathijssen RH, Sparreboom A, Verweij J (2014) Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 11:272–281

18. Miniasian L, Rosen O, Auclair D, Rahman A, Pazdur R, Schilsky RL (2014) Optimizing dosing of oncology drugs. Clin Pharmacol Ther 96:572–579

19. Lu D, Lu T, Stroh M et al (2016) A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities. Cancer Chemother Pharmacol 77:459–476

20. Heinig K, Miya K, Kamei T et al (2016) Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment. Bioanalysis 8:1465–1479

21. Sato-Nakai M, Kawashima K, Nakagawa T et al (2017) Metabolites of alectinib in human: their identification and pharmacological activity. Heliyon 3:e00354

22. Morcos PN, Cleary Y, Guerini E et al (2017) Clinical drug-drug Interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib. Clin Pharmacol Drug Dev 6:280–291

23. Morcos PN, Guerini E, Parrott N et al (2017) Effect of food and esomeprazole on the pharmacokinetics of alectinib, a highly selective ALK inhibitor. Clin Pharmacol Drug Dev 6:280–291

24. Morcos PN, Yu L, Bogman K et al (2017) Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects. Xenobiotica 47:217–229

25. Fowler S, Morcos PN, Cleary Y et al (2017) Progress in prediction and interpretation of clinically relevant metabolic drug-drug interactions: a mini review illustrating recent developments and current opportunities. Curr Pharmacol Rep 3:36–49

26. Center for Drug Evaluation and Research (2012) Clinical Pharmacology and Biopharmaceutics Review(s) for Rogarafenib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000ClinPharmR.pdf. Accessed 10 Feb 2018

27. Center for Drug Evaluation and Research (2013) Clinical Pharmacology and Biopharmaceutics Review(s) for Dabrafenib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000ClinPharmR.pdf. Accessed 10 Feb 2018

28. Center for Drug Evaluation and Research (2006) Clinical Pharmacology and Biopharmaceutics Review(s) for Sunitinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_S000_Sunitinib_BioPharmR.pdf. Accessed 10 Feb 2018

29. Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc Ser B 34:187–220

30. Fox J, Weisberg S (2010) Cox proportional-hazards regression for survival data in R. An appendix to an R companion to applied regression, Second Edition. Sage Publications, Los Angeles

31. Shaw AT, Solomon B (2011) Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 17:2081–2086

32. Hsu JC, Carnac R, Henschel V et al (2016) Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population. J Clin Oncol 34(Suppl):Abstract e20598

33. Gadgeel S, Gandhi L, Riely G et al (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002IG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119–1128

34. Center for Drug Evaluation and Research (2011) Clinical Pharmacology and Biopharmaceutics Review(s) for Crizotinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf. Accessed 10 February 2018

35. Yamazaki S, Vicini P, Shen Z et al (2012) Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther 340:549–557

36. Nickens D, Tan W. Exposure-response analysis of efficacy and safety endpoints for crizotinib in the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC). http://www.acop7.org/assets/Legacy_ACOPs/ACoP6/poster_abstracts/4-2.pdf. Accessed 10 February 2018

37. Kezirer R, Huitema AD, Schellens JH, Beijnen JH et al (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493–507

38. Motta G, Carbone E, Spinelli E et al (1999) Considerations about tumor size as a factor of prognosis in NSCLC. Ann Ital Chir 70:893–897

39. Zhan JG, Gold KA, Lin HY et al (2015) Relationship between tumor size and survival in non-small cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol 10:682–690

40. Jamal-Hanjani M, Wilson GA, McGranahan N et al (2017) Tracking the evolution of non-small-cell lung cancer. N Engl J Med 376:2109–2121

41. Zhang LL, Kan M, Zhang MM et al (1999) Considerations about kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther 340:549–557

42. Solomon B, Wilner KD, Shaw AT et al (2014) Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin Pharmacol Ther 95:15–23

43. Center for Drug Evaluation and Research (2014) Clinical Pharmacology and Biopharmaceutics Review(s) for Ceritinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf. Accessed 10 February 2018

44. Hong Y, Passos VQ, Huang PH et al (2017) Population pharmacokinetics of ceritinib in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase. J Clin Pharmacol 57:652–662